Hubei Biocause Pharmaceutical (SHE:000627) — Market Cap & Net Worth
Market Cap & Net Worth: Hubei Biocause Pharmaceutical (000627)
Hubei Biocause Pharmaceutical (SHE:000627) has a market capitalization of $1.13 Billion (CN¥7.75 Billion) as of May 4, 2026. Listed on the SHE stock exchange, this China-based company holds position #8572 globally and #2236 in its home market, demonstrating a 13.67% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hubei Biocause Pharmaceutical's stock price CN¥1.58 by its total outstanding shares 4904139165 (4.90 Billion). Analyse how efficiently does Hubei Biocause Pharmaceutical generate cash to see how efficiently the company converts income to cash.
Hubei Biocause Pharmaceutical Market Cap History: 2015 to 2025
Hubei Biocause Pharmaceutical's market capitalization history from 2015 to 2025. Data shows change from $7.18 Billion to $1.13 Billion (-14.93% CAGR).
Hubei Biocause Pharmaceutical Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hubei Biocause Pharmaceutical's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.04x
Hubei Biocause Pharmaceutical's market cap is 0.04 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $7.18 Billion | $1.08 Billion | $247.27 Million | 6.65x | 29.04x |
| 2016 | $5.11 Billion | $8.18 Billion | $1.78 Billion | 0.62x | 2.87x |
| 2017 | $5.36 Billion | $8.99 Billion | $1.33 Billion | 0.60x | 4.05x |
| 2018 | $3.79 Billion | $11.05 Billion | $1.33 Billion | 0.34x | 2.86x |
| 2019 | $4.77 Billion | $12.62 Billion | $1.78 Billion | 0.38x | 2.69x |
| 2020 | $3.36 Billion | $12.30 Billion | $580.29 Million | 0.27x | 5.80x |
| 2021 | $2.29 Billion | $12.20 Billion | $470.71 Million | 0.19x | 4.87x |
| 2022 | $2.19 Billion | $49.62 Billion | $274.05 Million | 0.04x | 8.00x |
| 2023 | $2.04 Billion | $49.59 Billion | -$651.76 Million | 0.04x | N/A |
Competitor Companies of 000627 by Market Capitalization
Companies near Hubei Biocause Pharmaceutical in the global market cap rankings as of May 4, 2026.
Key companies related to Hubei Biocause Pharmaceutical by market ranking:
- China Life Insurance Co Ltd A (SHG:601628): Ranked #210 globally with a market cap of $111.74 Billion USD ( CN¥763.60 Billion CNY).
- Ping An Insurance Group Co of China Ltd (SHG:601318): Ranked #278 globally with a market cap of $92.61 Billion USD ( CN¥632.89 Billion CNY).
- Manulife Financial Corp (TO:MFC): Ranked #410 globally with a market cap of $64.53 Billion USD ( CA$89.20 Billion CAD).
- Ping An Insurance (Group) Company of China Ltd (F:PZX): Ranked #436 globally with a market cap of $60.05 Billion USD ( €51.37 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #210 | China Life Insurance Co Ltd A | SHG:601628 | $111.74 Billion | CN¥36.67 |
| #278 | Ping An Insurance Group Co of China Ltd | SHG:601318 | $92.61 Billion | CN¥59.37 |
| #410 | Manulife Financial Corp | TO:MFC | $64.53 Billion | CA$53.20 |
| #436 | Ping An Insurance (Group) Company of China Ltd | F:PZX | $60.05 Billion | €6.90 |
Hubei Biocause Pharmaceutical Historical Marketcap From 2015 to 2025
Between 2015 and today, Hubei Biocause Pharmaceutical's market cap moved from $7.18 Billion to $ 1.13 Billion, with a yearly change of -14.93%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | CN¥1.13 Billion | -66.17% |
| 2024 | CN¥3.35 Billion | +64.44% |
| 2023 | CN¥2.04 Billion | -7.03% |
| 2022 | CN¥2.19 Billion | -4.37% |
| 2021 | CN¥2.29 Billion | -31.86% |
| 2020 | CN¥3.36 Billion | -29.53% |
| 2019 | CN¥4.77 Billion | +26.03% |
| 2018 | CN¥3.79 Billion | -29.40% |
| 2017 | CN¥5.36 Billion | +4.94% |
| 2016 | CN¥5.11 Billion | -28.82% |
| 2015 | CN¥7.18 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Hubei Biocause Pharmaceutical was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.13 Billion USD |
| MoneyControl | $1.13 Billion USD |
| MarketWatch | $1.13 Billion USD |
| marketcap.company | $1.13 Billion USD |
| Reuters | $1.13 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Hubei Biocause Pharmaceutical
Hubei Biocause Pharmaceutical Co., Ltd. primarily provides life and motor insurance products in China. It also engages in the pharmaceutical, chemical, and new energy fuel businesses. In addition, the company is involved in the contract research and production of APIs, intermediates, and formulations, including tablets, granules, capsules, etc.; and provision of chemicals comprising dimethyl ethe… Read more